AVN 66.50 Increased By ▲ 1.65 (2.54%)
BOP 8.80 Increased By ▲ 0.10 (1.15%)
CHCC 131.50 Increased By ▲ 7.29 (5.87%)
DCL 9.25 Increased By ▲ 0.35 (3.93%)
DGKC 103.94 Increased By ▲ 3.05 (3.02%)
EFERT 61.60 No Change ▼ 0.00 (0%)
EPCL 44.50 Increased By ▲ 1.50 (3.49%)
FCCL 20.61 Increased By ▲ 0.21 (1.03%)
FFL 14.25 Increased By ▲ 0.43 (3.11%)
HASCOL 14.08 Increased By ▲ 0.51 (3.76%)
HBL 129.89 Increased By ▲ 1.07 (0.83%)
HUBC 79.63 Increased By ▲ 1.13 (1.44%)
HUMNL 6.60 Increased By ▲ 0.10 (1.54%)
JSCL 23.10 Increased By ▲ 0.80 (3.59%)
KAPCO 28.20 Increased By ▲ 0.57 (2.06%)
KEL 3.71 Increased By ▲ 0.10 (2.77%)
LOTCHEM 12.73 Increased By ▲ 0.26 (2.09%)
MLCF 38.19 Increased By ▲ 1.67 (4.57%)
OGDC 103.07 Increased By ▲ 5.53 (5.67%)
PAEL 32.30 Increased By ▲ 1.45 (4.7%)
PIBTL 12.12 Increased By ▲ 0.25 (2.11%)
PIOC 90.29 Increased By ▲ 6.79 (8.13%)
POWER 9.48 Increased By ▲ 0.31 (3.38%)
PPL 93.22 Increased By ▲ 5.30 (6.03%)
PSO 195.07 Increased By ▲ 4.79 (2.52%)
SNGP 43.18 Increased By ▲ 0.44 (1.03%)
STPL 13.42 Increased By ▲ 0.17 (1.28%)
TRG 57.38 Increased By ▲ 4.48 (8.47%)
UNITY 23.38 Decreased By ▼ -0.24 (-1.02%)
WTL 1.02 Increased By ▲ 0.02 (2%)
BR100 4,252 Increased By ▲ 58.16 (1.39%)
BR30 21,403 Increased By ▲ 315.18 (1.49%)
KSE100 41,031 Increased By ▲ 653.5 (1.62%)
KSE30 17,295 Increased By ▲ 278.41 (1.64%)
World

China's Sinovac COVID-19 vaccine appears safe in last stage trials: Researchers

  • Butantan Institute states CoronaVac proved to be safe in a trial so far involving 9,000 volunteers
Updated 20 Oct 2020

(Karachi) In a last stage clinical trial, an experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe, preliminary results showed.

Brazil's leading bio-medical research centre Butantan Institute engaged in carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

But the research institute's director Dimas Covas said that results of the data on vaccine's effectiveness will not be released till completion of the trial. The trial is being conducted on 13,000 volunteers.

He stated that researchers will keep monitoring the participants in the on-going trial. He mentioned there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain

It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

Earlier, the China-based biopharmaceutical company Sinovac Biotech started Phase III clinical trial of its inactivated Covid-19 vaccine in Turkey. The company has already performed Phase I/II studies of the vaccine in volunteers aged 18 to 59 years and those aged 60 years old and above, at Jiangsu and Hebei Provinces on April 16 and May 22, respectively, in China.